拜耳利伐沙班片上市时间

(Rivaroxaban) is a direct factor Xa inhibitor that can activate factor X into factor Xa through both endogenous and exogenous pathways, and thus plays an anticoagulant effect. The drug has very high bioavailability and a relatively short half-life, and can take effect within a short period of time, helping to alleviate the clinical symptoms and signs of patients with acute pulmonary embolism. Compared with warfarin, this drug is basically not affected by factors such as drugs and food during use. It does not require close monitoring of the patient's coagulation function, and there is no need to adjust the dosage. It is simpler and more convenient to use, and has high patient tolerance.

The Bayer Group has always promoted the transformation of its prescription drug business with breakthroughs in pharmaceutical innovation, which made research and development once the core competitiveness of Bayer Healthcare's multinational development, such as contrast agents, hemophilia, multiple sclerosis, etc. In addition to the research and development of new drugs, Bayer Healthcare also focuses on improving existing products and exploring new potential. As a drug owned by Bayer in Germany, the launch of rivaroxaban has undoubtedly brought new opportunities and choices for many patients' treatment. Moreover, the drug has relatively significant efficacy and is a trustworthy product. So, when will Bayer’s Rivaroxaban tablets be launched?

Bayer's rivaroxaban tablets were first approved for marketing in Canada on September 15, 2008, and later approved for marketing by the European Union on October 1, 2008. In June 2009, the drug was approved for marketing in China under the trade name Xarelto. Later, in July 2011, it was approved by the FDA for official marketing in the United States.

When purchasing the drug, patients should note that patients who are allergic to Rivaroxaban or any excipients in the tablets, those with lesions or conditions that pose a significant risk of major bleeding, and those with clinically significant active bleeding should use Rivaroxaban with caution or stop using it.

Recommended hot articles: /newsDetail/96950.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.